Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
HFE	3077	EPOETIN ALFA	CHEMBL1201565		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
HFE	rs1799945	G	epoetin alfa	"dosage","metabolism/PK"	yes	Required dosage to maintain a fixed hemoglobin target level was lower. Required iron dose was also lower in carriers, but not significantly. Please note: carriers of this mutation or the rs1800562 C282Y mutation were pooled together. The alleles were not specified in the study, however G allele corresponds to the H63D (CAT>GAT) loss of function mutation.	Allele G is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele C.	18025780	769171145
HFE	rs1799945	G	atenolol	efficacy	no	Not significant when using Bonferroni-corrected alpha of 0.0014. Response was assessed by change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 9 weeks of treatment.	Allele G is not associated with response to atenolol in people with Hypertension as compared to allele C.	23087401	1183491501
HFE	rs1800562	A	epoetin alfa	"dosage","metabolism/PK"	yes	Required dosage to maintain a fixed hemoglobin target level was lower. Required iron dose was also lower in carriers, but not significantly. Please note: carriers of this mutation or the rs1799945 H63D mutation were pooled together. The alleles were not specified in the study, however the A allele corresponds to the C282Y (TGC>TAC) loss of function mutation.	Allele A is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele G.	18025780	769171171
HFE	rs2071303	CC + CT	adalimumab	efficacy	yes	Alleles given as A and G. Based on inflammatory bowel disease questionnaire at week 20. Also looked at 4, 12, and 30 weeks after initiation of treatment. Response defined as increased in IBDQ of more than 22 points, or as IBDQ higher than 170 points.	Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT.	27115882	1447983363